. Produced by mesothelial cells, this biological marker appeared to be strongly correlated with the presence of effusions and abdominal involvement. The association with B symptoms or bone marrow involvement has also been described in some studies (1, 4, 6, 7, 9, 10 ). Finally, CA125 serum level at diagnosis has been reported to be a new prognostic factor (1, 4, 6, 7) and it has been proposed to incorporate it in the current prognostic index. On the other hand, CA125 levels have rarely been examined in patients with Hodgkin's disease (HD) .
In this study, we analyzed the clinical characteristics associated with elevated CA125 levels at diagnosis and examined whether abnormal CA125 serum levels were associated with altered overall survival (OS) or progressive-free survival (PFS) in 99 patients with HD or NHL.
Patients and methods

Patients
Between July 2000 and January 2005, 99 consecutive patients hospitalized in our center with newly diagnosed NHL or HD underwent serum CA125 assessment at diagnosis. Their characteristics are detailed in Table 1 . Tumors were classified according to the REAL classification (11) . The extent of the disease was evaluated by means of physical examination, computed tomography of the chest, abdomen and pelvis, total body PET scanner, bone marrow biopsy, as well as other investigations depending on clinical symptoms and signs. Staging was defined on the basis of the Ann Arbor classification (12) . Performance status was assessed according to the Eastern Cooperative Oncology Group scale.
Laboratory analyses
All laboratory analyses were determined on fresh samples collected on the same day at diagnosis. Serum CA125 was measured on a Modular E170 autoanalyser by Electrochemiluminescence Immunoassay (Roche, Basel, Switzerland) with a measuring range of 0.6-5000 UI/mL (reference range 0-35 UI/mL). Serum b 2 -microglobulin (Radioimmunoassay; Immunotech, Prague, Czech Republic, reference range 1-2.5 mg/L), serum lactate deshydrogenase (LDH) (enzymatic UV-assay; Roche, reference range 240-480 UI/L), hemoglobin (Cyanmethemoglobin method; Bayer Technicon, Tarrytown, NY, USA) and Creactive protein (CRP) (Immunoturbidimetric assay; Roche) were also obtained in all patients.
Statistical analyses
Results were expressed as means ± standard deviations, medians and ranges for continuous variables and as percentages for categorical variables. Biological parameters were log-transformed whenever appropriate. Patients with normal or elevated CA125 levels were compared by logistic regression for each variable separately but also for all variables combined into a backward selection procedure (13) . OS and PFS were evaluated by Cox regression models with application of a backward selection procedure. Multivariate analyses were carried out by adjusting for the histological group and in the case of OS and PFS for CA125 levels. Results were considered to be significant at the 5% level (P < 0.05). Data analysis was carried out using SAS 9.1 for Windows (SAS Institute, Cary, NC, USA) statistical package.
Results
Characteristics of the patients (demography, clinical and biological parameters) are listed in Table 1 for the total population and within each histological group. There were 27 patients with indolent NHL (Lymphocytic lymphoma n ¼ 1, follicular lymphoma n ¼ 15, malt lymphoma n ¼ 6, unclassified n ¼ 5), 51 with aggressive NHL (Diffuse large B cell lymphoma n ¼ 39, mantle cell lymphoma n ¼ 6, anaplastic large cell lymphoma n ¼ 2, periperal T-cell lymphoma n ¼ 3, Burkitt's lymphoma n ¼ 1) and 21 patients with HD (Nodular lymphocyte-predominant HD n ¼ 3, nodular sclerosis HD n ¼ 16, mixed cellularity HD n ¼ 1, unclassified HD n ¼ 1). There were 42 (42%) women and 57 (58%) men, mean age was 57 ± 18 yr (median 58 yr, range 15-88 yr). Among patients, 17% had poor performance status, 22% presented B symptoms, 58% had an advanced clinical stage, 50% abdominal, 40% mediastinal and 28% bone marrow involvement, and 14% an effusion. The aaIPI was ‡1 in 37% of the patients.
CA125 serum level was 105 ± 368 UI/mL and was elevated in 34 patients (34%). Proportions of patients with elevated CA125 serum levels did not significantly differ among the three histological groups (indolent NHL: 19%, aggressive NHL: 45%, HD: 29%; P ¼ 0.059). There was also no significant difference for age (P ¼ 0.46) and sex (P ¼ 0.86). Patients with elevated CA125 serum levels had more frequently poor performance status (37% vs. 8%, P ¼ 0.0015), B symptoms (42% vs. 11%, P ¼ 0.0009), advanced clinical stage (88% vs. 42%, P < 0.0001), abdominal (74% vs. 37%, P ¼ 0.0008), mediastinal (62% vs. 29%, P ¼ 0.002) or bone marrow (47% vs. 19%, P ¼ 0.004) involvement and presence of effusions (36% vs. 2%, P ¼ 0.0009). They had also higher aaIPI (75% vs. 17%, P < 0.0001). Finally, they exhibited lower Hb levels (12 ± 2.4 vs. 14 ± 1.9 g/dL, P ¼ 0.002), higher CRP (58 ± 83 vs. 21 ± 33 mg/L, P ¼ 0.0003), LDH (900 ± 883 vs. 500 ± 530 UI/L, P < 0.0001) and b2-microglobulin (4.1 ± 2.7 vs. 2.2 ± 1.3 mg/L, P < 0.0001) levels.
When the analysis was restricted to patients with indolent lymphomas, those with elevated CA125 serum levels had more often mediastinal involvement (60% vs. 14%, P ¼ 0.042), higher aaIPI (60% vs. 10%, P ¼ 0.024), higher LDH (564 ± 186 vs. 348 ± 82 UI/L, P ¼ 0.022), CRP (25 ± 23 vs. 7 ± 10 mg/L, P ¼ 0.049) and b2-microglobulin (5.0 ± 2.8 vs. 2.1 ± 0.8 mg/L, P ¼ 0.024) levels.
In aggressive NHL, patients with elevated CA125 serum levels had more frequently poor performance status (40% vs. 11%, P ¼ 0.028), B symptoms (41% vs. 4%, P ¼ 0.0091), advanced clinical stage (96% vs. 46%, P ¼ 0.003), abdominal (78% vs. 32%, P ¼ 0.0017), mediastinal (52% vs. 18%, P ¼ 0.013) or bone marrow (44% vs. 11%, P ¼ 0.012) involvement, high aaIPI (81% vs. 30%, P ¼ 0.0009), low Hb (12 ± 2.5 vs. 14 ± 1.7 g/dL, P ¼ 0.027), high CRP (63 ± 91 vs. 24 ± 34 mg/L, P ¼ 0.043), LDH (1051 ± 1045 vs. 677 ± 778 UI/L, P ¼ 0.0081) or b2-microglobulin (4.3 ± 2.9 vs. 2.5 ± 1.7 mg/ L, P ¼ 0.0057) levels. In multivariate analysis adjusted for histological group, only bone marrow involvement (P ¼ 0.032), the presence of effusion (P ¼ 0.009) and high aaIPI (P ¼ 0.002) were significantly associated with high CA125 serum levels.
OS was significantly worse for patients with poor performance status hazard ratio (HR ¼ 5.1, P < 0.0005), B symptoms (HR ¼ 4.3, P ¼ 0.0014), advanced clinical stage (HR ¼ 3.3, P ¼ 0.033), bone marrow involvement (HR ¼ 2.8, P ¼ 0.02), high aaIPI (HR ¼ 5.3, P ¼ 0.0006), low Hb (HR ¼ 0.03, P ¼ 0.001), high CRP (HR ¼ 1.5, P ¼ 0.007) and high b2-microglobulin (HR ¼ 5.9, P < 0.0001) ( Table 2 , Fig. 1 ). Progressionfree survival (PFS) was significantly worse for older patients (HR ¼ 1. Table 2 ). OS and PFS were not different in patients with normal or elevated CA125 levels.
In multivariate Cox models, when adjusting for CA125 levels and for histological group, OS and PFS were significantly affected adversely only by high b2-microglobulin (OS: HR ¼ 7.1, P < 0.0001; PFS: HR ¼ 5.9, P < 0.0001) ( Table 3 ). For PFS, we also noted a worse outcome for men (HR ¼ 2.7, P ¼ 0.015). There was no effect of CA125 levels (OS, P ¼ 0.18; PFS, P ¼ 0.48) and no difference between histological groups (OS: P > 0.5; PFS: P > 0.5).
Discussion
In this study, we retrospectively evaluated the significance of CA125 serum levels in 99 patients with lymphoma. We first analyzed the clinical and biological characteristics associated with elevated CA125 levels at diagnosis. High CA125 serum levels were observed in 34% of the patients. This percentage is comparable with figures previously reported by other authors (2, (5) (6) (7) (14) (15) (16) (17) . In univariate analysis, many characteristics of more advanced disease were associated with elevated CA125 values. However, in multivariate analysis, an association was only found between high CA125 serum levels, on the one hand, and the presence of effusions, marrow involvement and high aaIPI, on the other. These results have been previously found by others (1, 2, 4-10, 17) .
It is now proven that it is not the malignant lymphocytes but mesothelial cells that produce CA125 (1, 4, 5, 10, 14) . Inflammatory cytokines, such as IL-1 and TNFa, produced by macrophages and lymphoma cells, are suspected to stimulate CA125 (1, 4, 14) , but also IL-6 and IL-8 production (5, 15) . The presence of effusion or the involvement of serous membranes (such as the peritoneum, pericardium or pleura) can thus enhance CA125 production by mesothelial cells (1, 2) . Because of CA125 production by cells other than lymphoma cells, its serum levels are more a reflection of the inflammatory response to the disease than of the tumor mass itself. As cytokine production is proportional to the tumor mass (15), it is not surprising that CA125 are mostly found in association with various characteristics of advanced disease. We now have good prognostic factors, such as the aaI-PI (3) for aggressive NHL and the FLIPI (18) for follicular lymphoma. Given the association of CA125 levels with higher aaIPI, the gold standard of prognostic evaluation of lymphoma patients, one could predict that CA125 levels would not enhance that prognostic assessment. Indeed, CA125 serum levels did not improve its performance in our study. It would therefore be inappropriate to take therapeutic decisions based on CA125 serum levels.
Some authors have reported worse outcome in patients with high CA125 levels (1, 4, 7, 8) . In univariate analysis, Bairey et al. (4) found significantly worse OS in patients with aggressive NHL and elevated CA125 but this biological factor lost its prognostic significance in multivariate analysis. Zacharos et al. (1) observed 5-yr survival of 65% vs. 20% in patients with aggressive NHL and normal or elevated CA125, respectively. This difference remained significant in multivariate analysis. Benboubker et al. (7) reported significantly better outcome in patients with low-grade NHL and normal CA125 levels but the results of multivariate analyses are unknown. Finally, in a study of 38 patients, Zidan et al. (6) showed inferior OS for patients with aggressive NHL and high CA125 levels (5-yr OS: 35% vs. 76%, respectively). This difference remained significant after the population was split into histological subgroups. We were not able to confirm this. In our series, only b2-microglobulin worsened PFS or OS. This result has already been reported and is now well validated (15) . These contradictory results could be related to different patient populations and treatments, and should be better investigated in multicenter studies including more patients, receiving the same treatment and presenting homogenous histological and clinical features.
The role of CA125 levels in the early detection of relapse in CA125-producing patients has also been reported (1, 2, 4, 6) . Perhaps, other methods, such as PET scans or combined CT-PET scans (19) , would be more efficient, though more costly but this remains to be prove. However, the decrease of CA125 serum levels during therapy could be an argument for adequate tumor response to therapy in so far as there are no concomitant abdominal, pericardial or pleural abnormalities.
In conclusion, while CA125 serum level correlates with a number of features associated with more aggressive disease, it does not enhance the performance of standard prognostic factors in the treatment of patients with NHL or HD. 
